HIV Therapeutics Market Headed for Growth and Global Expansion by 2020
Rise in research activities for developing HIV vaccines and lack of awareness about the modes of transmission of the virus are driving the global market for HIV therapeutics.
New York, NY -- (SBWire) -- 01/18/2017 --HIV infection has no cure but there are treatments which help to stabilize or reduce this infection so that it does not lead to AIDS. HIV therapeutics market is growing at a significant rate due to increase in the HIV infected cases and growing awareness about the same. HIV infection can be treated by various therapeutics such as nucleoside/ nucleotide reverse transcriptase inhibitor, integrase inhibitor, HIV-1 protease inhibitor, non-nucleoside reverse transcriptase inhibitor, pharmacokinetic enhancer and entry inhibitor.
A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/3339
The human immunodeficiency virus (HIV) refers to a type of retrovirus that causes acquired immunodeficiency syndrome (AIDS). HIV attacks some immune cells and causes weakness of immune system resulting in loss of ability to fight against the organism that causes disease. HIV spreads through fluidic exchange with some infected person such as blood transfer or sharing needles with someone who is HIV infected. In addition, HIV can spread from infected mother to child during pregnancy. Some of the symptoms of HIV infection are slight fever, fatigue, swollen glands, headaches and muscle aches.
North America, followed by Europe, has the largest market for HIV therapeutics due to affordability and accessibility of expensive treatment for HIV infection and innovations in drug therapies in this region. Asia is expected to show high growth rate in the HIV therapeutics market in next few years due to increasing number of HIV infected population and increasing research activities for developing HIV drugs and vaccines in the region.
Increasing number of HIV infection cases, technological advancement in HIV diagnosis and therapeutics, rise in research activities for developing HIV vaccines and lack of awareness about the modes of transmission of the virus are driving the global market for HIV therapeutics. In addition, increasing awareness about the availability of HIV therapeutics in the market and cost effective drug therapies for HIV are driving the global HIV therapeutics market. However, various factors such as failure of treatment in some cases, lack of skilled professionals and introduction of generic drugs in the market are restraining the HIV therapeutics market.
Growing demographics and economies in the developing countries such as India and China are expected to offer good opportunities for HIV therapeutics market. In addition, rise in awareness about the availability of treatment of HIV infection are expected to offer new opportunity to global HIV therapeutics market. One of the latest trends that have been observed in the HIV therapeutics market includes companies involved in new product launches.
To view TOC of this report is available upon request @ http://www.persistencemarketresearch.com/toc/3339
Some of the major companies dealing in HIV therapeutics are GlaxoSmithKline, Bristol-Myers Squibb, Pfizer and Boehringer Ingelheim. Other companies having significant presence in HIV therapeutics market are Merck, Hoffmann-La Roche and Gilead Sciences.
Media Relations Contact
Persistence Market Research Pvt. Ltd.
View this press release online at: http://rwire.com/761382